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Abstract
Background: Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in adults. MN is a clinically
heterogeneous disease and it is difficult to accurately predict outcomes (including end stage renal failure) at presentation
and whom to treat with potentially toxic therapies. We aimed to identify factors predicting outcome in MN in our cohort
from two large tertiary London units by undertaking a retrospective data analysis of 148 biopsy-proven MN patients from
North East and Central London between 1995 and 2015.
Methods: Review of clinical and biochemistry databases.
Results: Surprisingly, patients that reached end stage renal failure (ESRF) had a less severe nephrosis compared to those
that did not develop ESRF; serum albumin 33 g/L (3.3 g/dL) versus 24 g/L (2.4 g/dL), p = 0.002 and urinary protein
creatinine ratio (uPCR) 550 mg/mmol (5500 mg/g) versus 902 mg/mmol (9020 mg/g), p = 0.0124. The correlation with
ESRF was strongest with the presenting creatinine; 215 μmol/L (2.43 mg/dL) compared to 81 μmol/L (0.92 mg/dL), p < 0.
0001. Patients presenting with creatinine of >120 μmol/L (1.36 mg/dL; corresponding to an eGFR of ≤60 ml/min in non-
Black males) had an increased rate of ESRF and a faster decline. Other traditional risk factors for progression were not
significantly associated with ESRF.
Black patients presented with higher serum creatinine but no statistically significant difference in the estimated
glomerular filtration rate, a higher rate of progression to ESRF and had a poorer response to treatment.
Conclusions: This ethnically diverse cohort does not demonstrate the traditional risk profile associated with
development of ESRF. Thus, careful consideration of therapeutic options is crucial, as current risk modelling cannot
accurately predict the risk of ESRF. Further studies are required to elucidate the role of antibodies and risk genes.
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Background
Idiopathic membranous nephropathy (IMN) is a serious
autoimmune renal disease that is the leading cause of
adult nephrotic syndrome and can progress to end stage
renal failure (ESRF). Secondary forms exist that are attrib-
utable to an underlying cause. In all patients with mem-
branous nephropathy (MN) the pathogenesis involves the
development of autoantibodies against antigens present
on podocytes. Classic autoimmune disorders have a strong
female preponderance [1, 2], whereas with MN males are
predominantly affected (with a ratio of approximately 3:1).
MN has a variable natural history and tends to develop in
a stratified way. It demonstrates an approximate ‘rule of
thirds’: in untreated patients, spontaneous complete re-
mission of proteinuria occurs in 5-30% at 5 years [3–5],
spontaneous partial remission in 25-40% at 5 years [3–5]
and progression to ESRF in 41% at 5 years [4, 6]. The risk
of progressing to ESRF is increased in those who are older
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at presentation, have nephrotic range proteinuria and/or
decreased glomerular filtration rate (GFR) at presentation;
interestingly it is also increased in males [3, 7, 8]. Asian
patients appear to have a better prognosis than non-
Asians [7].
Immunomodulatory treatment for MN includes cyclo-
phosphamide (CYC), chlorambucil, calcineurin inhibi-
tors (CNI) - such as cyclosporine A and tacrolimus,
rituximab, anti-proliferative agents (AP) - such as myco-
phenolate mofetil and azathioprine - and corticosteroids.
These all predispose to opportunistic infections. Alkylat-
ing agents, the gold standard treatment recommended
by KDIGO [9], increase cancer risk threefold [10]. To
lessen exposure to these therapeutic toxins, there has
been much interest in predicting MN patients at risk of
progression to ESRF. The predictive accuracy of heavy
proteinuria is only 30–50%, and risk modeling with mul-
tiple clinical variables (still based on data from 1997)
yields a disappointing 80% accuracy rate [11].
Published studies describe ethnically homogenous pa-
tient cohorts [4, 12, 13] and therefore we were interested
to see if there were differences at diagnosis, treatment or
response rate within two tertiary renal London units that
cover an extensive and ethnically diverse area of North
East and Central London. This retrospective study was
undertaken to ascertain if there are differences in our
patient population, treatment strategies and remission
rates compared to those previously reported.
Methods
Patient selection
Our study was performed across two tertiary London
Renal Units – The Royal Free Hospital and the Royal
London Hospital. We identified adult patients with
membranous nephropathy (MN) by searching the clin-
ical renal databases at both centres. We excluded pa-
tients that did not have MN. Two hundred forty patients
were identified with biopsy proven MN. A further 92 pa-
tients were excluded from analysis as there was no serial
data available for the 2 year period after the diagnosis of
MN was made. The remaining 148 patients were in-
cluded in the study. Of these 148, 121 had IMN, 4 de
novo MN in renal transplants and 23 secondary MN.
The patients with secondary MN had a range of causes:
14 systemic lupus erythematosus, 1 scleroderma, 6 hepa-
titides, 1 malignancy and 1 tuberculosis. The study was
retrospective so did not need ethical approval as per
NHS Health Research Authority regulation.
Data collection
Data were collected using the renal databases in addition
to local clinical pathology databases. The date of the bi-
opsy was considered to be month 0 – (date of diagnosis)
and subsequent data collection based thereafter on this
date. Serial data was collected at diagnosis, 1, 2, 3, 6, 12,
18 and 24 months. At each time point serum creatinine,
albumin, urine protein creatinine ratio, haemoglobin,
immunoglobulins and bicarbonate were recorded. Add-
itionally, the use of renin angiotensin system blocker
(RASB) or immunosuppression was recorded at each
month. Rates of complications, co-morbidities as well as
demographic data such as gender, age and ethnicity was
collected. Remission status was calculated based on the
standard criteria for complete and partial remission [13].
Analysis of results
A retrospective analysis was then performed and data ana-
lysed using Graphpad Prism 6 (Graphpad software, USA).
For parametric data, t-tests were used to compare two data
sets, and Mann-Whitney tests for non-parametric data.
Contingency tables were analysed with Chi square tests and
more than three data sets were compared with ANOVA
analysis. Prism 6 was used to formulate the graphs.
Results
Baseline characteristics
A total of 148 patients were included in this retrospect-
ive study. The baseline characteristics of the study popu-
lation are described in Table 1.
Differences at diagnosis
In our study population there were significant differences
between characteristics at diagnosis in those that reached
Table 1 Table demonstrating baseline characteristics of all
patients. Values are given either as median with interquartile
range (IQR) or mean with standard deviation (SD) or percentages
Number of cases 148
Gender Ratio (Male: Female) n 90: 58
Median Age 58 (47–71)
Ethnicity (Asian: Black: White: Unknown) % 31: 24: 36: 9
Median Diagnosis Serum creatinine μmol/L (IQR)
(mg/dL)
92 (68–183)
(1.04, 0.77–2.07)
Median Diagnosis Serum albumin g/L (IQR)
(g/dL)
25 (20–31)
(2.5, 2–3.1)
Median Diagnosis urine protein creatinine ratio
mg/mmol (IQR) (mg/g)
776 (432 – 1172)
(7760, 4320–11,720)
Median Diagnosis cholesterol mmol/L (IQR)
(mg/dL)
7.5 (5.75–9.25)
(290, 222–357)
Median Diagnosis bicarbonate mmol/L (IQR) 25 (23–28)
Mean Diagnosis haemoglobin g/L (SD) 124.8 (21.68)
Co-morbidities: Hypertension / Diabetes /
Recurrent UTIs / Malignancy / Mental health
issues n
38 / 24 / 4 / 1 / 2
Complications: thrombotic event / treatment
related side effect %
13 / 5
Renin angiotensin system blockade medication
use %
84
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ESRF and those that did not. The serum creatinine was
significantly higher in those reaching ESRF, 215 μmol/L
(124–360) (2.43 mg/dL, 1.4–4) compared to those that
did not reach ESRF, 81 μmol/L (64–120) (0.92 mg/dL,
0.72–1.36), p < 0.0001; Fig. 1. At each time point reviewed,
the difference in the serum creatinine remained statisti-
cally significant (month 1, 2, 3, 6, 12, 18 and 24); all p-
values <0.0001. Serum bicarbonate was lower compared
to non-ESRF patients; 21.8 mmol/L ± 0.78 versus
26.0 mmol/L ± 0.45 in non-ESRF patients, p < 0.0001.
Finally, haemoglobin was also lower in those that reached
ESRF; 111.5 g/L ± 2.5 compared to 127.7 g/L ± 2.3,
p = 0.0001.
Patients reaching ESRF had less severe nephrotic syn-
drome at presentation with a higher serum albumin; me-
dian 33 g/L (27–39) (3.3 g/dL) compared to non-ESRF
patients; 24 g/L (19–30) (2.4 g/dL), p = 0.0002 (Fig. 2).
The uPCR was also lower in ESRF patients; 550 mg/
mmol (213–985) (5500 mg/g, 2130–9850) compared to
902 mg/mmol (532–1314) (9020 mg/g, 5320–13,140),
p = 0.0124. The serum cholesterol was lower in patients
with ESRF and less severe nephrotic syndrome;
5.7 mmol/L (4.4–7.9) (220 mg/dL, 170–305) compared
to non-ESRF patients 7.9 mmol/L (6–9.8) (305 mg/dL,
232–378), p = 0.008.
There was no significant difference in gender distri-
bution between the ESRF and non-ESRF groups, the
proportion of men reaching ESRF was 27% compared
to 22% women, in contrast to 73% of men being non-
ESRF and 78% women, p = 0.56. There was also no
difference in the mean age at presentation (58 ± 1.7
in the non-ESRF group compared to the ESRF group
59 ± 2.4, p = 0.67).
Multivariate analysis with a 2-way ANOVA and Bon-
ferroni correction demonstrated that only two significant
variables were associated with developing ESRF; the
diagnosis serum creatinine and uPCR. Serum creatinine
was higher in those reaching ESRF with lower uPCR, p-
values 0.0134 and <0.0001 respectively.
Progression of biochemical parameters
Detailed biochemistry was analysed for the 2 years fol-
lowing biopsy diagnosis in all patients. Over this period
there was no significant change in the serum creatinine
in the non-ESRF patients. There was also no change in
the serum bicarbonate or haemoglobin. There was a sig-
nificant reduction in the cholesterol over the follow up
period with treatment; 7.8 mmol/L (301 mg/dL) at ad-
mission compared to 4.8 mmol/L (185 mg/dL) at 2 years,
p < 0.0001. The albumin significantly incremented up to
41 g/L (4.1 g/dL) compared to 24 g/L (2.4 g/dL) at diag-
nosis, p < 0.0001. This mirrored a reduction in uPCR;
903 mg/mmol (9030 mg/g) at diagnosis compared to
119 mg/mmol (1190 mg/g), p < 0.0001.
Our patient cohort has a median follow up of 84 months,
(longest 211 months / 17.5 years). We therefore examined
long-term data on those reaching ESRF. A serum cut off
of <120 μmol/L (1.36 mg/dL) was used as this represents
an estimated GFR (eGFR) of 60 ml/min/1.73m2 (using the
abbreviated MDRD formula) in a 50 year old non-Black
male. Of patients presenting with a creatinine of
<120 μmol/L (1.36 mg/dL) only 10% (9 of 89) reached
ESRF within a median time to ESRF of 178 months (under
15 years). Patients with a creatinine >120 μmol/L
(1.36 mg/dL) however had an increased rate of developing
ESRF; 29 out of 54 (54%) and at a quicker rate with a me-
dian time period of 117 months (under 10 years), this dif-
ference is statistically significant, p < 0.0001, Fig. 3.
Ethnicity differences
Our study population are ethnically diverse, enabling direct
comparisons between different ethnic groups. There is an
approximate equal spread over the different ethnic groups;
Table 2. There was no significant difference in the age at
diagnosis for these different groups (mean age – Asian 57,
Black 57, White 60). Median creatinine was significantly
higher in Black patients (103 μmol/L / 1.17 mg/dL) com-
pared to Asian (69.5 μmol/L / 0.79 mg/dL) and White
Fig. 1 Difference between serum creatinine at presentation between
patients ultimately reaching ESRF and non-ESRF
Fig. 2 Difference between serum albumin at presentation between
patients reaching ESRF and non-ESRF
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(87.5 μmol/L / 0.99 mg/dL), ANOVA p = 0.0443. However,
there was no statistically significant difference between
MDRD eGFR though there was a trend to lower eGFR in
Black patients. Black patients eGFR was 67 ml/min/
1.73m2, White patients 71 ml/min/1.73m2 and Asian pa-
tients the highest at 86 ml/min/1.73m2. Despite this, Black
patients were more likely to reach ESRF (43%) compared
to Asian (20%) and White (19%) patients, Chi-square
p < 0.0001, see Fig. 4. White patients have higher complete
remission rates at 1 year (19%) compared to Asian patients
(6.6%) p = 0.029, and Black patients (11%) p = 0.059.
Immunosuppression & Remission Status
One hundred patients were treated with immunosup-
pression and 48 were treated conservatively. The differ-
ent therapeutic options and usage rates are summarised
in Table 3. All treatments were accompanied by steroids
in the form of either oral prednisolone or intravenous
methylprednisolone. Those receiving immunosuppres-
sion were younger, compared to those treated conserva-
tively (median age of 55 vs. 66 yrs. old, p = 0.0016).
There was no difference in the creatinine, albumin or
uPCR at diagnosis between those that were treated ei-
ther conservatively or immunosuppressed. Additionally,
there was no difference in these three parameters at
1 year between these two groups.
Rates of complete remission were highest with CYC at
25%, the least effective immunosuppressants to achieve
complete remission were CNIs at 16%. This contrasts to
no immunosuppression with a complete remission rate
of 6% and AP agents at 24%. The partial remission rate
was better with immunosuppression rather than conser-
vative treatment 29% (CYC 38%, CNI 37%, AP 33%).
The lowest rate of no remission was in the CYC group
at 36% compared to CNI 47%, AP 43% and conservative
management 54%. This suggests superiority of cyclo-
phosphamide in our patient cohort, however the results
did not reach statistical significance. Black patients were
less likely to be treated with CNI (18%) and more likely
to be treated with CYC (31%).
Patients undergoing complete remission were youn-
ger (mean age 55) compared to both partial and non-
responders (61 and 59 respectively). Responders to
treatment, irrespective of treatment strategy, had a
lower creatinine at presentation; median 87 μmol/L
(0.98 mg/dL) compared to 120 μmol/L (1.36 mg/dL) in
the non-responders, p = 0.0116. Additionally, re-
sponders had lower serum albumin at diagnosis com-
pared to the non-responders (albumin 25.5 ± 0.9 gl/L
(2.6 g/dL) compared to 28.5 ± 1.2 g/L (2.9 g/dL),
p = 0.0476), but there was no statistically significant
difference in the uPCR.
Fig. 3 Survival graph showing time to renal failure and difference
between presentation creatinine and survival at 5 years
Table 2 Ethnic diversity, number of patients and percentages of
different ethnicities within our cohort
Ethnic group N (%)
Asian 45 (31)
Black 35 (24)
White 54 (36)
Subgroups
African 14
Caribbean 21
Bangladeshi 9
Chinese 5
Indian 17
Pakistani 9
Middle Eastern 5
Fig. 4 Difference in ethnicities and resultant ESRF rates
Table 3 Different therapeutic options used in our cohort
Treatment N (%)
Conservative 48 (32)
Cyclophosphamide 36 (24)
Calcineurin inhibitors 38 (26)
Antiproliferative agents (MMF/azathioprine) 21 (14)
Rituximab/steroid monotherapy/other 1/3/1 (Total 3%)
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Discussion
This study corroborates findings from previous studies
that conclude patients presenting with impaired renal
function are more likely to reach ESRF in MN. [14].
However, at odds with these studies, we have shown that
our ESRF patients actually present less nephrotic than
the non-ESRF patients. The traditional paradigm is that
the worse the proteinuria, the worse the risk of ESRF;
patients are even risk stratified for treatment based on
the degree of proteinuria in MN [7, 12, 15]. In our co-
hort, patients who were less nephrotic but with worse
renal function progressed to ESRF. This may reflect the
reduced glomerular filtration rate attenuating protein-
uria, resulting in less severe nephrosis [16].
The other known risk factors for ESRF in MN are gen-
der and age [14]; neither were statistically significant in
our group. Further, high lipid levels have been found to
contribute to glomerulosclerosis and therefore ESRF in-
dependent to the severity of nephrosis [17]; however, we
found that patients progressing to ESRF had lower
serum cholesterol concentrations, emphasising the at-
tenuated nephrosis in the progression group.
Our data supports the main predictor for progression
to ESRF in MN being the serum creatinine at diagnosis.
In our cohort, at least, it appears that some of the trad-
itional known risk factors for the development of ESRF
with MN are less reliable than previously reported. This
is not a trivial matter, as strategies to give toxic treat-
ments for MN are currently based on these risk factors.
A significant limitation to our study is the lack of anti-
phospholipase A2 receptor antibody status. This was
due to the retrospective nature of the study and the lack
of historical serum samples, we are now in a process of
collecting anti-PLA2R antibody status of all patients in
our tertiary MN clinics. Antibody positivity and titre are
important as these are associated with severity and out-
come of disease [18, 19].
Ethnic differences
This ethnically diverse group of patients revealed some in-
teresting data. Where details of ethnicity were made avail-
able, MN has been reported in homogenous ethnic groups
[4, 12, 13]. We found Black patients had worse serum cre-
atinine and lower eGFR (though the eGFR difference was
not statistically significant), were more likely to progress
to ESRF and were treated more often with cyclophospha-
mide. There are no comparable studies or reports in Black
patients with MN, however, these findings are similar to
studies in other renal diseases. It is known that age, sex,
race and body weight affect serum creatinine concentra-
tion, some of this difference may be due to higher baseline
serum creatinine levels found in Black patients and this
explains why eGFR differences were not statistically sig-
nificant [20]. Black patients with lupus nephritis have
deteriorating renal function and reduced survival com-
pared to other ethnic groups [21]. Black patients with an
eGFR >60 ml/min have a faster rate of decline in renal
function irrespective of their albuminuria compared with
White patients [22]. The rate of decline persists despite
correction of traditional risk factors such as albuminuria,
diabetes and hypertension, which suggests an underlying
genetic mechanism [22, 23]. There are no studies of MN
outcomes in different ethnic groups, however a recent
study reviewed the distribution of glomerulopathies in a
Southern Californian population. Overall they had lower
rates of Black (18.6%) and Asian (8.8%) patients and a lar-
ger proportion of Hispanic patients compared to our co-
hort [24]. There are some reports that Black patients do
not respond to CYC as well as other AP agents [21].
There are differences in socioeconomic and biological
factors that may explain the faster rate of decline to
ESRF in Black patients. Important proposed mechanisms
are an interaction of sociodemographic factors with gen-
etic factors such as lower socioeconomic status, chronic
stress, psychosocial factors, environmental pollution and
differences in access to health care [22]. It should be
noted that, like many other studies, we grouped ethnic-
ally discrete groups of patients together. For instance,
the Asian group included both Indo-Asian and East-
Asian patients and the Black group included African and
Caribbean patients; these populations are, of course,
genetically diverse.
Knowledge about MN has changed significantly as
have treatment strategies [4, 12, 13] since the start of the
study period. For future studies of MN patients, anti-
body status and tissue immunohistochemistry of im-
mune deposits and markers of chronic damage
correlates are warranted. Furthermore, genomic data
would offer insights into the links between ethnicity,
gender and outcomes.
Conclusions
This ethnically diverse cohort does not demonstrate the
traditional risk profile associated with development of
ESRF. Those responding to treatment have more severe
nephrotic syndrome, whereas those reaching ESRF have
the worst renal function and lowest proteinuria at diag-
nosis. There are ethnic differences with Black patients
presenting with a trend to lower eGFR and having an in-
creased risk of ESRF. This study highlights the import-
ance of careful consideration of therapeutic options, as
current risk modelling cannot accurately predict the risk
of ESRF. Further studies are required to elucidate the
role of antibodies and risk genes.
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